Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $775000.0.

  • Perspective Therapeutics' Depreciation & Amortization (CF) rose 1584.45% to $775000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 5529.23%. This contributed to the annual value of $2.3 million for FY2024, which is 13387.42% up from last year.
  • As of Q3 2025, Perspective Therapeutics' Depreciation & Amortization (CF) stood at $775000.0, which was up 1584.45% from $733000.0 recorded in Q2 2025.
  • Perspective Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $775000.0 during Q3 2025, with a 5-year trough of -$78000.0 in Q4 2021.
  • For the 5-year period, Perspective Therapeutics' Depreciation & Amortization (CF) averaged around $329055.6, with its median value being $257000.0 (2023).
  • In the last 5 years, Perspective Therapeutics' Depreciation & Amortization (CF) plummeted by 31081.08% in 2021 and then soared by 28656.72% in 2023.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Depreciation & Amortization (CF) stood at -$78000.0 in 2021, then soared by 276.92% to $138000.0 in 2022, then surged by 118.84% to $302000.0 in 2023, then skyrocketed by 134.77% to $709000.0 in 2024, then grew by 9.31% to $775000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $775000.0 in Q3 2025, compared to $733000.0 in Q2 2025 and $732000.0 in Q1 2025.